Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10564923 | 0.78 | HRH3 (0.42) | SIGMAR1CYP2D6 | |
| SCHEMBL11139471 | 0.75 | TSHR (0.43) | SIGMAR1 | |
| SCHEMBL9034462 | 0.73 | DRD2 (0.43) | SIGMAR1 | |
| SCHEMBL5945677 | 0.73 | HTR2C (0.38) | SIGMAR1 | |
| SCHEMBL3204729 | 0.72 | SIGMAR1 (0.45) | SIGMAR1CYP2D6 | |
| SCHEMBL6160907 | 0.69 | P2RX7 (0.56) | SIGMAR1 | |
| SCHEMBL25642096 | 0.69 | HPGD (0.60) | SIGMAR1 | |
| SCHEMBL6163189 | 0.68 | HTR2C (0.57) | SIGMAR1 | |
| SCHEMBL6170302 | 0.66 | SIGMAR1 (0.53) | SIGMAR1CYP2D6 | |
| SCHEMBL5068319 | 0.65 | ALDH1A1 (0.61) | SIGMAR1CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100029682-A1 | NOVEL CHROMENE AND THIOCHROMENE CARBOXAMIDE DERIVATIVES, METHODS FOR PREPARING SAME AND THERAPEUTIC APPLICATIONS OF SAME | PIERRE FABRE MEDICAMENT (FR) | 2010-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029682-A1 | NOVEL CHROMENE AND THIOCHROMENE CARBOXAMIDE DERIVATIVES, METHODS FOR PREPARING SAME AND THERAPEUTIC APPLICATIONS OF SAME | DRD3, CHRNA3, CHRM3 | SIGMAR1 109/4885CYP2D6 896/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.